Peter Radovich Sells 2,382 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 2,382 shares of the business’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total transaction of $222,312.06. Following the completion of the sale, the chief operating officer owned 20,679 shares in the company, valued at approximately $1,929,971.07. This trade represents a 10.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Mirum Pharmaceuticals Trading Down 1.8%

MIRM traded down $1.74 on Friday, hitting $94.29. The company had a trading volume of 802,708 shares, compared to its average volume of 890,067. The business’s fifty day simple moving average is $76.87 and its 200 day simple moving average is $70.34. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals, Inc. has a 12-month low of $36.88 and a 12-month high of $96.84. The company has a market cap of $4.85 billion, a PE ratio of -109.64 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.15. The business had revenue of $133.01 million during the quarter, compared to analyst estimates of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company’s revenue for the quarter was up 47.1% on a year-over-year basis. During the same period last year, the company earned ($0.30) EPS. Equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analyst Upgrades and Downgrades

MIRM has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Wednesday, October 8th. Citizens Jmp upped their price target on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the company a “market outperform” rating in a report on Friday, December 19th. Morgan Stanley increased their price objective on shares of Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 9th. Evercore ISI reissued an “outperform” rating and issued a $101.00 price objective on shares of Mirum Pharmaceuticals in a research note on Tuesday. Finally, Leerink Partners set a $100.00 target price on Mirum Pharmaceuticals in a research report on Wednesday, December 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $102.58.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. CWM LLC increased its holdings in shares of Mirum Pharmaceuticals by 30.8% in the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after acquiring an additional 161 shares during the period. Legal & General Group Plc lifted its stake in shares of Mirum Pharmaceuticals by 0.4% during the 2nd quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock worth $2,189,000 after purchasing an additional 176 shares during the last quarter. MCF Advisors LLC boosted its position in Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after purchasing an additional 185 shares in the last quarter. Teacher Retirement System of Texas grew its stake in Mirum Pharmaceuticals by 2.2% in the second quarter. Teacher Retirement System of Texas now owns 9,903 shares of the company’s stock valued at $504,000 after purchasing an additional 215 shares during the last quarter. Finally, Palumbo Wealth Management LLC grew its stake in Mirum Pharmaceuticals by 4.2% in the second quarter. Palumbo Wealth Management LLC now owns 5,604 shares of the company’s stock valued at $285,000 after purchasing an additional 228 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.